

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/132923 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2021/063551

(22) International Filing Date:

15 December 2021 (15.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/126,024 16 December 2020 (16.12.2020) US

(71) Applicant: **VOYAGER THERAPEUTICS, INC.**
[US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: **KURELLA, Vinodhbabu**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **LIU, Li**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **KAVANAGH, Dillon**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **CAPILLI, Allan, D.**; 12 Dimick Street, Somerville, MA 02143 (US). **HOU, Jinzhao**; 9 Tyler Road, Lexington, MA 02420 (US). **CARTER, Todd**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **LIU, Wencheng**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: **LU, Yu** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TAU BINDING COMPOUNDS

(57) Abstract: The present disclosure provides anti-tau antibodies. Also provided are methods of using anti-tau antibodies for treatment and diagnosis of neurological indications.

WO 2022/132923 A1